Recently, Shandong Xinbo Drug Research Co., Ltd. has been successfully selected into the provincial-level 2026 scenario capability list in Shandong Province, thanks to its core technical strength, comprehensive service system, and outstanding innovation ability in the field of preclinical drug safety evaluation!

Demonstrate Shandong Xinbo's leading position and core competitiveness in the biopharmaceutical R&D service sector, and establish it as a benchmark enterprise for scenario innovation in the field of life and health.

Deeply cultivating the field of safety assessment, laying a solid foundation for innovation
As a national high-tech enterprise and Shandong Provincial Enterprise Technology Center, Shandong Xinbo has been focusing on the core field of preclinical drug safety evaluation since its establishment in 2010. It has established a one-stop scientific research service system encompassing pharmacodynamics, toxicology, drug analysis, pathological testing, and medical device evaluation.

The company has established two major laboratories in Jinan and Linyi, with over 20,000 square meters of experimental space that meets international standards. Equipped with over 800 domestic and international instruments and equipment, it strictly adheres to NMPA, FDA, and GLP standards. It is capable of conducting toxicological research for certified projects, covering various types of drug evaluations such as small molecules, biological macromolecules, vaccines, traditional Chinese medicine, and cell and gene therapy products.

Being selected into the provincial list, we will continue to write a new chapter of development
The successful inclusion in the Shandong Provincial Scene Capability List is a high recognition of the company's technological capabilities, innovation level, and industry contributions by Shandong Province. It is also an important opportunity for the company to integrate into the province's new quality productivity development layout and empower the high-quality development of the biopharmaceutical industry.

In the future, Shandong Xinbo will use this as a driving force to continuously increase research and development investment, refine core technologies, improve service ecology, and with stronger core strength and more professional services, help more innovative drugs move from laboratories to clinical trials, providing technical service support for the development of Shandong's biopharmaceutical industry.